• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Arcimoto Shares Are Trading Lower By 44%; Here Are 20 Stocks Moving Premarket

    1/18/23 7:50:09 AM ET
    $APTX
    $ATER
    $ATXI
    $BTCM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Home Furnishings
    Consumer Discretionary
    Get the next $APTX alert in real time by email

    Gainers

    • Siyata Mobile Inc. (NASDAQ:SYTA) rose 41.5% to $0.3255 in pre-market trading after gaining 8% on Tuesday.
    • Faraday Future Intelligent Electric Inc. (NASDAQ:FFIE) rose 26.4% to $0.60 in pre-market trading after the company announced strategic agreement with the City of Huanggang and signed a new shareholder agreement with FF Global Partners.
    • Celyad Oncology SA (NASDAQ:CYAD) shares rose 26.4% to $2.41 in pre-market trading after jumping 138% on Tuesday. Celyad Oncology recently issued an update on its Celyad 2.0 business strategy, which has been adopted and implemented over the last few months.
    • Avenue Therapeutics, Inc. (NASDAQ:ATXI) shares rose 15.1% to $2.29 in pre-market trading after climbing over 60% on Tuesday. Avenue Therapeutics, during November, posted a Q3 loss of $0.45 per share.
    • PaxMedica, Inc. (NASDAQ:PXMD) shares rose 14% to $3.34 in pre-market trading after gaining around 17% on Tuesday.
    • AVITA Medical, Inc. (NASDAQ:RCEL) rose 12.4% to $9.05 in pre-market trading after gaining around 7% on Tuesday. AVITA Medical, last month, submitted FDA PMA application to expand indication to vitiligo.
    • Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) rose 10.6% to $1.25 in pre-market trading. Citius Pharmaceuticals, last month, reported FY22 earnings results.
    • Aterian, Inc. (NASDAQ:ATER) rose 9.8% to $1.46 in pre-market trading. Aterian shares gained 37% on Tuesday after the company issued Q4 revenue guidance above analyst estimates.
    • Healthcare Triangle, Inc. (NASDAQ:HCTI) rose 8.7% to $0.25 in pre-market trading. Healthcare Triangle, during November, posted a Q3 loss of $0.06 per share.
    • Moderna, Inc. (NASDAQ:MRNA) rose 6.5% to $203.00 in pre-market trading after the company's syncytial virus vaccine candidate met its primary endpoint in a Phase 3 trial.

     

    Losers

    • Arcimoto, Inc. (NASDAQ:FUV) fell 44.4% to $3.40 in pre-market trading after the company reported a proposed public offering.
    • IronNet, Inc. (NYSE:IRNT) shares fell 11.8% to $0.3601 in pre-market trading. IronNet, last month, announced receipt of noncompliance letter from NYSE.
    • The Very Good Food Company Inc. (NASDAQ:VGFC) fell 10.5% to $0.06 in pre-market trading. The Very Good Food Company announced the receivership order, suspension of trading and board member resignation.
    • Edesa Biotech, Inc. (NASDAQ:EDSA) fell 8.9% to $1.33 in pre-market trading. Edesa Biotech shares dropped around 42% on Tuesday after the company reported topline Phase 2b results for its dermatology drug.
    • Hour Loop, Inc. (NASDAQ:HOUR) shares fell 8.7% to $2.61 in pre-market trading after gaining over 5% on Tuesday.
    • SOS Limited (NYSE:SOS) fell 7.7% to $7.56 in pre-market after jumping around 20% on Tuesday.
    • BIT Mining Limited (NYSE:BTCM) shares dropped 6.8% to $4.06 in pre-market trading. BIT Mining shares jumped 42% on Tuesday after the company announced the launch of a new energy efficient LiteCoin/DogeCoin Miner, LD3.
    • Calyxt, Inc. (NASDAQ:CLXT) fell 6.3% to $0.3310 in pre-market trading. Calyxt shares jumped over 90% on Tuesday after the company and Cibus announced a definitive merger agreement.
    • Aptinyx Inc. (NASDAQ:APTX) fell 6.3% to $0.46 in pre-market trading. Aptinyx , during November, posted a Q3 loss of $0.23 per share.
    • MultiMetaVerse Holdings Limited (NASDAQ:MMV) fell 5.5% to $2.71 in pre-market trading. MultiMetaVerse recently announced a letter of intent to acquire a majority equity stake in Taomee.
    Get the next $APTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APTX
    $ATER
    $ATXI
    $BTCM

    CompanyDatePrice TargetRatingAnalyst
    Avita Medical Inc.
    $RCEL
    3/5/2026$10.00Outperform
    Northland Capital
    Moderna Inc.
    $MRNA
    1/28/2026$25.00Equal Weight
    Barclays
    Moderna Inc.
    $MRNA
    1/7/2026$34.00Neutral
    UBS
    Moderna Inc.
    $MRNA
    12/12/2025$30.00Hold
    Jefferies
    Avita Medical Inc.
    $RCEL
    11/20/2025Sell → Neutral
    BTIG Research
    Avita Medical Inc.
    $RCEL
    8/8/2025$3.00Neutral → Sell
    BTIG Research
    Moderna Inc.
    $MRNA
    3/13/2025$40.00Neutral
    Citigroup
    Moderna Inc.
    $MRNA
    2/18/2025$111.00 → $45.00Overweight → Equal Weight
    Barclays
    More analyst ratings

    $APTX
    $ATER
    $ATXI
    $BTCM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Edesa Biotech Inc.

    4 - Edesa Biotech, Inc. (0001540159) (Issuer)

    3/11/26 5:02:18 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Avita Medical Inc.

    4 - AVITA Medical, Inc. (0001762303) (Issuer)

    3/11/26 4:30:07 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Nijhawan Pardeep bought $6,599 worth of shares (1,000 units at $6.60), increasing direct ownership by 0.16% to 628,813 units (SEC Form 4)

    4 - Edesa Biotech, Inc. (0001540159) (Issuer)

    3/10/26 5:02:16 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APTX
    $ATER
    $ATXI
    $BTCM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Healthcare Triangle, Inc. Announces Approval of $2 Million Share Repurchase Plan

    PLEASANTON, Calif., March 11, 2026 /CNW/ -- Healthcare Triangle, Inc. (NASDAQ:HCTI) ("HCTI" or the "Company"), a leader in digital transformation solutions including managed services, cloud enablement, and data analytics for the healthcare and life sciences industries, today announces that its Board of Directors has approved a share repurchase program authorizing the Company to repurchase up to $2,000,000 of its outstanding common stock ("2026 Share Repurchase Plan"). The 2026 Share Repurchase Plan was approved by the Company's Board of Directors on March 9, 2026, and became effective immediately. Under the newly authorized plan, the Company may repurchase shares of its common stock from tim

    3/11/26 4:10:00 PM ET
    $HCTI
    EDP Services
    Technology

    Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers

    Study data from patients with relapsed or refractory gynecologic cancers signals the potential of LYMPHIR to augment immune checkpoint inhibitor efficacyTopline data of University of Pittsburgh-led trial to be presented at an upcoming international cancer conference later this yearCRANFORD, N.J., March 10, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (NASDAQ:CTXR), today announced positive topline results from a completed investigator‑initiated Phase 1 clinical trial conducted by University of Pittsburgh investigators. This study evalu

    3/10/26 8:47:00 AM ET
    $CTOR
    $CTXR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma

    Topline data of investigator‑initiated study at the University of Minnesota and City of Hope demonstrates 86% overall response rate (OR), including 57% complete response (CR) and 29% partial response (PR)LYMPHIR was well-tolerated with no dose-limiting toxicities observedCRANFORD, N.J., March 4, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (NASDAQ:CTXR), today announced positive topline safety and efficacy results from an investigator‑initiated Phase 1 trial evaluating LYMPHIR™ (E7777, denileukin diftitox‑cxdl) administered prior to co

    3/4/26 9:15:00 AM ET
    $CTOR
    $CTXR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APTX
    $ATER
    $ATXI
    $BTCM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Northland Capital initiated coverage on Avita Medical with a new price target

    Northland Capital initiated coverage of Avita Medical with a rating of Outperform and set a new price target of $10.00

    3/5/26 8:30:26 AM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    Barclays resumed coverage on Moderna with a new price target

    Barclays resumed coverage of Moderna with a rating of Equal Weight and set a new price target of $25.00

    1/28/26 7:18:07 AM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    UBS resumed coverage on Moderna with a new price target

    UBS resumed coverage of Moderna with a rating of Neutral and set a new price target of $34.00

    1/7/26 9:12:19 AM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APTX
    $ATER
    $ATXI
    $BTCM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Nijhawan Pardeep bought $6,599 worth of shares (1,000 units at $6.60), increasing direct ownership by 0.16% to 628,813 units (SEC Form 4)

    4 - Edesa Biotech, Inc. (0001540159) (Issuer)

    3/10/26 5:02:16 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Nijhawan Pardeep bought $39,000 worth of shares (10,000 units at $3.90) (SEC Form 4)

    4 - Edesa Biotech, Inc. (0001540159) (Issuer)

    3/6/26 5:01:15 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Nijhawan Pardeep bought $42,560 worth of shares (10,000 units at $4.26) (SEC Form 4)

    4 - Edesa Biotech, Inc. (0001540159) (Issuer)

    3/5/26 5:01:11 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APTX
    $ATER
    $ATXI
    $BTCM
    SEC Filings

    View All

    SEC Form DEF 14A filed by Moderna Inc.

    DEF 14A - Moderna, Inc. (0001682852) (Filer)

    3/16/26 4:31:50 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form DEFA14A filed by Moderna Inc.

    DEFA14A - Moderna, Inc. (0001682852) (Filer)

    3/16/26 4:32:27 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SCHEDULE 13G filed by Edesa Biotech Inc.

    SCHEDULE 13G - Edesa Biotech, Inc. (0001540159) (Subject)

    3/16/26 4:00:02 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APTX
    $ATER
    $ATXI
    $BTCM
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    November 30, 2020 - Coronavirus (COVID-19) Update: FDA Announces Advisory Committee Meeting to Discuss Second COVID-19 Vaccine Candidate

    For Immediate Release: November 30, 2020 The U.S. Food and Drug Administration has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Dec. 17 to discuss the request for emergency use authorization (EUA) for a COVID-19 vaccine from Moderna, Inc. “In keeping with the FDA’s commitment to ensuring full transparency, dialogue and efficiency, the Vaccines and Related Biological Products Advisory Comm

    11/30/20 5:12:14 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APTX
    $ATER
    $ATXI
    $BTCM
    Leadership Updates

    Live Leadership Updates

    View All

    Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board

    WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced it has appointed François Nader, M.D., MBA, as an independent director to its Board of Directors, effective April 1, 2026, at which time he will also assume the role of Chair of the Board. Dr. Nader brings more than 30 years of leadership experience across the biotechnology and pharmaceutical industry and currently serves as an Independent Director of Moderna, Inc. (NASDAQ:MRNA), a glo

    2/23/26 4:01:00 PM ET
    $MRNA
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    AVITA Medical Announces Changes to its Board of Directors

    Veteran healthcare executive Joe Woody joins the BoardLou Panaccio retires after over a decade of service VALENCIA, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. ((ASX: AVH, NASDAQ:RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced the appointment of Joe Woody as a new non-executive Director and the retirement of Lou Panaccio, who served as Chairman from July 2014 to August 2025. "We are pleased to welcome Joe to the Board. His extensive track record leading global med-tech companies and driving commercial excellence will be invaluable as we continue to scale AVITA Medical's growth," said Cary Vance, Interim CEO of

    1/5/26 4:05:00 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    SOLAI Limited Joins RWA Alliance as a Founding Member to Advance Tokenization of Green Energy Assets

    AKRON, Ohio, Oct. 21, 2025 /PRNewswire/ -- SOLAI Limited (NYSE: SLAI) ("SOLAI" or the "Company"), a leading technology-driven cryptocurrency infrastructure company (previously known as "BIT Mining"), today announced that it has officially joined the Real-World Assets (RWA) Alliance as one of its founding members. The RWA Alliance is dedicated to solving critical industry pain points – such as asset liquidity and opaque valuation – by promoting the tokenization of real-world assets. By leveraging blockchain technology to standardize, divide, and bring transparency to physical assets, the Alliance aims to open up new pathways for the digital transformation of the green energy sector through r

    10/21/25 6:00:00 AM ET
    $BTCM
    EDP Services
    Technology

    $APTX
    $ATER
    $ATXI
    $BTCM
    Financials

    Live finance-specific insights

    View All

    AVITA Medical Reports Fourth Quarter and Full Year 2025 Financial Results

    VALENCIA, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company delivering transformative solutions ("AVITA Medical," or the "Company"), today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial Highlights and Recent Business Updates Total revenue of $17.6 million, compared to $18.4 million in the fourth quarter of 2024, reflecting the lingering impact of reimbursement headwinds throughout 2025.Gross profit margin of 81.2%, reflecting product mix and inventory-related adjustments.Net use of cash improved for the second consecutive quarter t

    2/12/26 4:01:00 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    AVITA Medical: Pre-J.P. Morgan Update Highlights 2025 Revenue Growth, New Debt Facility, and 2026 Growth Outlook

    VALENCIA, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. ((ASX: AVH, NASDAQ:RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced unaudited preliminary financial results and a business update for the fourth quarter and fiscal year 2025. The Company also provided its preliminary outlook for fiscal year 2026, ahead of its presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 at 5:15 p.m. Pacific Time (Thursday, January 15, 2026, at 12:15 p.m. Australian Eastern Daylight Time). The webcast can be accessed through AVITA Medical's website at: https://ir.avitamedical.com/events-and-presentations

    1/13/26 8:25:00 AM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update

    Subsidiary, Citius Oncology, launches cancer immunotherapy, LYMPHIR™, in the U.S. in December 2025 CRANFORD, N.J., Dec. 23, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ:CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal year ended September 30, 2025. "2025 was a pivotal year for Citius as we successfully launched LYMPHIR following its FDA approval, marking the first new systemic therapy for cutaneous T-cell lymphoma (CTCL) patients since 2018. This milestone reflects our ability to execute and our commitment t

    12/23/25 4:30:00 PM ET
    $CTOR
    $CTXR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APTX
    $ATER
    $ATXI
    $BTCM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Citius Pharmaceuticals Inc.

    SC 13D/A - Citius Pharmaceuticals, Inc. (0001506251) (Subject)

    11/27/24 4:05:31 PM ET
    $CTXR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Avenue Therapeutics Inc.

    SC 13D/A - AVENUE THERAPEUTICS, INC. (0001644963) (Subject)

    11/15/24 4:05:50 PM ET
    $ATXI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Siyata Mobile Inc.

    SC 13G/A - Siyata Mobile Inc. (0001649009) (Subject)

    11/14/24 7:28:44 PM ET
    $SYTA
    Telecommunications Equipment
    Telecommunications